Technical Analysis for IBRX - ImmunityBio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 4.10% | |
| Fell Below 200 DMA | Bearish | 4.10% | |
| Wide Bands | Range Expansion | 4.10% | |
| Crossed Above 20 DMA | Bullish | -5.14% | |
| Crossed Above 200 DMA | Bullish | -5.14% | |
| Wide Bands | Range Expansion | -5.14% | |
| Oversold Stochastic | Weakness | -5.14% | |
| Wide Bands | Range Expansion | 1.30% | |
| Oversold Stochastic | Weakness | 1.30% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 13.03% |
| Alert | Time |
|---|---|
| Up 5% | 34 minutes ago |
| Rose Above 10 DMA | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 2 hours ago |
| 10 DMA Resistance | about 3 hours ago |
| Up 3% | about 3 hours ago |
Get a Trading Assistant
- Earnings date: 11/06/2024
ImmunityBio, Inc. Description
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Cancer Treatment Cancer Immunotherapy Genomics Virotherapy Natural Killer Cell Lymphocytes Pelareorep
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.53 |
| 52 Week Low | 3.1 |
| Average Volume | 5,727,653 |
| 200-Day Moving Average | 5.27 |
| 50-Day Moving Average | 4.21 |
| 20-Day Moving Average | 5.21 |
| 10-Day Moving Average | 5.07 |
| Average True Range | 0.54 |
| RSI (14) | 51.22 |
| ADX | 34.96 |
| +DI | 25.63 |
| -DI | 17.56 |
| Chandelier Exit (Long, 3 ATRs) | 5.87 |
| Chandelier Exit (Short, 3 ATRs) | 4.98 |
| Upper Bollinger Bands | 6.06 |
| Lower Bollinger Band | 4.36 |
| Percent B (%b) | 0.3 |
| BandWidth | 32.55 |
| MACD Line | 0.20 |
| MACD Signal Line | 0.29 |
| MACD Histogram | -0.0849 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.68 | ||||
| Resistance 3 (R3) | 5.74 | 5.54 | 5.54 | ||
| Resistance 2 (R2) | 5.54 | 5.33 | 5.50 | 5.50 | |
| Resistance 1 (R1) | 5.21 | 5.20 | 5.10 | 5.14 | 5.45 |
| Pivot Point | 5.00 | 5.00 | 4.95 | 4.97 | 5.00 |
| Support 1 (S1) | 4.67 | 4.80 | 4.57 | 4.61 | 4.30 |
| Support 2 (S2) | 4.47 | 4.67 | 4.43 | 4.25 | |
| Support 3 (S3) | 4.14 | 4.47 | 4.21 | ||
| Support 4 (S4) | 4.07 |
